Scholarlink

<p>The treatment of tic disorders in children and adolescents poses significant challenges, especially when comorbid conditions such as obsessive-compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) are present. Pharmacological treatments are often guided by clinical judgment, prescriber preferences, and medication availability. This study describes pharmacological treatment use in a large cohort of children and adolescents with chronic tic disorders (CTDs). We analyzed baseline data from the European Multicenter Tics in Children Study (EMTICS) to examine associations between medication use, tic severity, and psychiatric comorbidities, using parent-reported questionnaires and clinical interviews to assess tics, obsessive-compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), and children’s self-rated premonitory urges. Among 709 children aged 3–16 years with CTDs, 230 (32%) received any pharmacological treatment, 22% received antipsychotics and 10% received ADHD medications, with limited use of alpha-2 agonists (3%). Medication use was more common among individuals with comorbid ADHD (54%) than those with CTD only (23%) or comorbid OCD only (26%). Those on tic-suppressing medications had significantly greater severity of tics, tic-related impairment, and comorbid ADHD, ODD, and obsessive symptom severity compared to those with non-tic-suppressing medications. There was no relationship with the severity of compulsions or premonitory urges. While largely consistent with published guidelines, these findings indicate limited utilization of recommended agents, such as alpha-2 agonists, alongside higher reported symptom severity among those receiving tic-suppressing medications. Further studies should explore the integration of pharmacological, behavioral, and psychoeducational approaches tailored to comorbidity profiles and symptom severity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Medication use and treatment patterns in children and adolescents with chronic tic disorders: an EMTICS study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月17日

查看全文
  • Orit Peled,
  • Daphna Shoham,
  • Tamar Steinberg,
  • Alan Apter,
  • Dana Feldman-Sadeh,
  • Miri Carmel,
  • Idan Barak,
  • Zsanett Tarnok,
  • Peter Nagy,
  • Abraham Weizman,
  • Pieter J. Hoekstra,
  • Andrea Dietrich,
  • Alan Apter,
  • Juliane Ball,
  • Noa Benaroya-Milshtein,
  • Judith Buse,
  • Francesco Cardona,
  • Marta Correa Vela,
  • Andrea Dietrich,
  • Carolin Fremer,
  • Blanca Garcia-Delgar,
  • Tammy J. Hedderly,
  • Isobel Heyman,
  • Pieter J. Hoekstra,
  • Chaim Huijser,
  • Marcos Madruga Garrido,
  • Davide Martino,
  • Pablo Mir,
  • Astrid Morer,
  • Norbert Müller,
  • Kirsten Müller-Vah,
  • Alexander Münchau,
  • Peter Nagy,
  • Kerstin J. Plessen,
  • Cesare Porcelli,
  • Renata Rizzo,
  • Veit Roessner,
  • Daphna Ruhrman,
  • Anette Schrag,
  • Tamar Steinberg,
  • Zsanett Tarnok,
  • Frank Visscher,
  • Susanne Walitza,
  • Elif Weidinger,
  • Noa Benaroya-Milshtein

摘要

The treatment of tic disorders in children and adolescents poses significant challenges, especially when comorbid conditions such as obsessive-compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) are present. Pharmacological treatments are often guided by clinical judgment, prescriber preferences, and medication availability. This study describes pharmacological treatment use in a large cohort of children and adolescents with chronic tic disorders (CTDs). We analyzed baseline data from the European Multicenter Tics in Children Study (EMTICS) to examine associations between medication use, tic severity, and psychiatric comorbidities, using parent-reported questionnaires and clinical interviews to assess tics, obsessive-compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), and children’s self-rated premonitory urges. Among 709 children aged 3–16 years with CTDs, 230 (32%) received any pharmacological treatment, 22% received antipsychotics and 10% received ADHD medications, with limited use of alpha-2 agonists (3%). Medication use was more common among individuals with comorbid ADHD (54%) than those with CTD only (23%) or comorbid OCD only (26%). Those on tic-suppressing medications had significantly greater severity of tics, tic-related impairment, and comorbid ADHD, ODD, and obsessive symptom severity compared to those with non-tic-suppressing medications. There was no relationship with the severity of compulsions or premonitory urges. While largely consistent with published guidelines, these findings indicate limited utilization of recommended agents, such as alpha-2 agonists, alongside higher reported symptom severity among those receiving tic-suppressing medications. Further studies should explore the integration of pharmacological, behavioral, and psychoeducational approaches tailored to comorbidity profiles and symptom severity.